Evaluation of the Efficacy of Rifaximin versus Mebeverine in the Treatment of Diarrhea-Predominant Irritable Bowel Syndrome
Rifaximin versus Mebeverine in the Treatment of Diarrhea-Predominant IBS
DOI:
https://doi.org/10.54393/pjhs.v7i3.3757Keywords:
Irritable Bowel Syndrome, Diarrhea-Predominant, Rifaximin, Functional Gastrointestinal DisordersAbstract
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a widespread functional gastrointestinal disease characterized by frequent abdominal pain and frequent looseness. Antispasmodics such as Mebeverine have proven effectiveness, whereas microbiota-targeted antibiotics such as Rifaximin could be more advantageous because of the effect on gut dysbiosis. Objectives: To compare the effectiveness of Rifaximin and Mebeverine to treat IBS-D through the treatment of diarrhea-predominant irritable bowel syndrome. Methods: This prospective comparative study was conducted at Khyber Teaching Hospital for six months from 1st January 2024 to 30th June 2024. Rifaximin or Mebeverine had been administered to the patients (n = 50 in each group). The collected data were the demographics, IBS Symptom Severity Score (IBS-SSS) at baseline, three months, and six months, and stool consistency, abdominal pain, bloating, and patient-reported satisfaction. The statistical analysis was performed with independent t-tests and chi-square tests; the p-value ≤ 0.05 was taken as significant. Results: Significantly greater improvements were observed in IBS-SSS in the Rifaximin group during three months (p=0.0002) and six months (p<0.0001) than in the Mebeverine group. Even though the Rifaximin group had better outcomes on categorical outcomes, such as stool normalization and first-line resolution of symptoms, most of them were not statistically significant. Conclusions: Rifaximin produced much improved symptomatic improvement as compared to Mebeverine in patients with IBS-D. The findings substantiate its use as a better treatment option clinically.
References
Aziz I and Simrén M. The Overlap Between Irritable Bowel Syndrome and Organic Gastrointestinal Diseases. The Lancet Gastroenterology and Hepatology. 2021 Feb; 6(2): 139-48. doi: 10.1016/S2468-1253(20)30212-0. DOI: https://doi.org/10.1016/S2468-1253(20)30212-0
Altomare A, Di Rosa C, Imperia E, Emerenziani S, Cicala M, Guarino MP. Diarrhea Predominant-irritable Bowel Syndrome (IBS-D): Effects of Different Nutritional Patterns on Intestinal Dysbiosis and Symptoms. Nutrients. 2021 Apr; 13(5): 1506. doi: 10.3390/nu13051506. DOI: https://doi.org/10.3390/nu13051506
Takeoka A, Kimura T, Hara S, Hamaguchi T, Fukudo S, Tayama J. Prevalence of Irritable Bowel Syndrome in Japan, China, and South Korea: An International Cross-Sectional Study. Journal of Neurogastroenterology and Motility. 2023 Apr; 29(2): 229. doi: 10.5056/jnm22037. DOI: https://doi.org/10.5056/jnm22037
Kim MY and Choi SW. Dietary Modulation of Gut Microbiota for the Relief of Irritable Bowel Syndrome. Nutrition Research and Practice. 2021 Aug; 15(4): 411-30. doi: 10.4162/nrp.2021.15.4.411. DOI: https://doi.org/10.4162/nrp.2021.15.4.411
Marasco G, Cremon C, Barbaro MR, Stanghellini V, Barbara G. Gut Microbiota Signatures and Modulation in Irritable Bowel Syndrome. Microbiome Research Reports. 2022 Mar; 1(2): 11. doi: 10.20517/mrr.2021.12. DOI: https://doi.org/10.20517/mrr.2021.12
Singh R, Zogg H, Wei L, Bartlett A, Ghoshal UC, Rajender S et al. Gut Microbial Dysbiosis in the Pathogenesis of Gastrointestinal Dysmotility and Metabolic Disorders. Journal Of Neurogastroenterology and Motility. 2021 Jan; 27(1): 19. doi: 10.5056/jnm20149. DOI: https://doi.org/10.5056/jnm20149
Daniluk J, Malecka-Wojciesko E, Skrzydlo-Radomanska B, Rydzewska G. The Efficacy of Mebeverine in the Treatment of Irritable Bowel Syndrome—A Systematic Review. Journal of Clinical Medicine. 2022 Feb; 11(4): 1044. doi: 10.3390/jcm11041044. DOI: https://doi.org/10.3390/jcm11041044
Al Ghamdi K, Albluwi N, Alammari A, Alibrahim H, Al-Thabet A, Radhi J et al. The Efficacy and Safety of Antispasmodic Agents in the Management of Irritable Bowel Syndrome: A Systematic Review. Journal of Health Science. 2023; 3: 167-80. doi: 10.52533/JOHS.2023.30602. DOI: https://doi.org/10.52533/JOHS.2023.30602
Deljavan Ghodrati A, Comoglu T. Rifaximin and Alternative Agents in the Management of Irritable Bowel Syndrome: A Comprehensive Review. Archiv der Pharmazie. 2024 Oct; 357(10): e2400356. doi: 10.1002/ardp.202400356. DOI: https://doi.org/10.1002/ardp.202400356
Mokhtare M, Fathi M, Sadeghian AM, Sotoudeheian MJ, Namazi A. A Pilot Study of the Effectiveness of a Short Course of Rifaximin 2200 mg/day on Abdominal Symptoms and Its Effects on Quality of Life in Patients with Moderate to Severe Diarrhea-Predominant Irritable Bowel Syndrome. Clinical Drug Investigation. 2024 Nov; 44(11): 839-47. doi: 10.1007/s40261-024-01403-w. DOI: https://doi.org/10.1007/s40261-024-01403-w
Oh CK, Chung HH, Kim YJ, Kim JB. Comparison of Rifaximin Monotherapy and Rifaximin Combined with Probiotics in Patients with Irritable Bowel Syndrome: A Randomized Controlled Trial. Nutrients. 2025 Feb; 17(5): 763. doi: 10.3390/nu17050763. DOI: https://doi.org/10.3390/nu17050763
Almonajjed MB, Wardeh M, Atlagh A, Ismaiel A, Popa SL, Rusu F et al. Impact of Microbiota on Irritable Bowel Syndrome Pathogenesis and Management: A Narrative Review. Medicina. 2025 Jan; 61(1): 109. doi: 10.3390/medicina61010109. DOI: https://doi.org/10.3390/medicina61010109
Anand K and Khatib MN. Causative Factors, Clinical Manifestations, and Therapeutic Strategies for Irritable Bowel Syndrome. Cureus. 2024 Apr; 16(4). doi: 10.7759/cureus.58728. DOI: https://doi.org/10.7759/cureus.58728
Mousavi T, Sharifnia M, Nikfar S, Abdollahi M. Pharmacotherapy for Gastric and Intestinal Cramping Pain: Current and Emerging Therapies. Expert Opinion on Pharmacotherapy. 2023 Dec; 24(18): 2021-33. doi: 10.1080/14656566.2023.2265830. DOI: https://doi.org/10.1080/14656566.2023.2265830
Qamer HM, Shamshad A, Bilal M. Efficacy of Rifaximin in Relieving Symptoms of IBS-D: Experience from a Public Hospital in Pakistan. Journal of Health, Wellness and Community Research. 2025 Jun: e305. doi: 10.61919/369fvt50. DOI: https://doi.org/10.61919/369fvt50
Anwar DF, Salma ZN, Oktaviani SD, Adiyatma FN, Tauhid FM, Mustofa A et al. Effect of Multistrain Probiotics on Symptom Severity in Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis of Irritable Bowel Syndrome–Symptom Severity Score Outcomes. European Journal of Gastroenterology and Hepatology. 2025 Dec: 10-97. doi: 10.1097/MEG.0000000000003074. DOI: https://doi.org/10.1097/MEG.0000000000003074
Black CJ and Ford AC. An Evidence-Based Update on the Diagnosis and Management of Irritable Bowel Syndrome. Expert Review of Gastroenterology and Hepatology. 2025 Mar; 19(3): 227-42. doi: 10.1080/17474124.2025.2455586. DOI: https://doi.org/10.1080/17474124.2025.2455586
Karki B, Sherpa TW, Deo RK, Thapa P. Clinical Response to Rifaximin Amongst Irritable Bowel Syndrome (IBS) Patients at Tertiary Level Hospital in Nepal. Journal of Patan Academy of Health Sciences. 2024 Jun; 11(1): 21-6. doi: 10.3126/jpahs.v11i1.65652. DOI: https://doi.org/10.3126/jpahs.v11i1.65652
Blankenberger A, Lesmana E, Yang L, Edwinson A, Breen-Lyles MK, Keehn A et al. 18 Longitudinal Assessment of Microbial Diversity Following Campylobacter Infection Associates with Proteolytic Activity Changes in Post-Infection Irritable Bowel Syndrome. Gastroenterology. 2024 May; 166(5): S-5. doi: 10.1016/S0016-5085(24)00507-9. DOI: https://doi.org/10.1016/S0016-5085(24)00507-9
Chey WD, Shah ED, DuPont HL. Mechanism of Action and Therapeutic Benefit of Rifaximin in Patients with Irritable Bowel Syndrome: A Narrative Review. Therapeutic Advances in Gastroenterology. 2020 Jan; 13: 1756284819897531. doi: 10.1177/1756284819897531. DOI: https://doi.org/10.1177/1756284819897531
Dumitrascu D, Bakulin I, Berzigotti A, Cravo M, Gombosova L, Lukas M et al. Update on the Role of Rifaximin in Digestive Diseases. Journal of Gastrointestinal and Liver Diseases. 2023; 32(1): 92-109. doi: 10.15403/jgld-4871. DOI: https://doi.org/10.15403/jgld-4871
Frias J, Martins M, Peixoto A, Macedo G. Rifaximin as a Therapeutic Ally in the Modulation of Dysbiosis: A Narrative Review of Its Applicability in Gastrointestinal Disorders. GE-Portuguese Journal of Gastroenterology. 2025 Apr; 32(6): 423–437. doi: 10.1159/000545926. DOI: https://doi.org/10.1159/000545926
Colomier E, Algera J, Melchior C. Pharmacological Therapies and Their Clinical Targets in Irritable Bowel Syndrome with Diarrhea. Frontiers in Pharmacology. 2021 Feb; 11: 629026. doi: 10.3389/fphar.2020.629026. DOI: https://doi.org/10.3389/fphar.2020.629026
Mousavi T, Nikfar S, Abdollahi M. An Update on Efficacy and Safety Considerations for the Latest Drugs Used to Treat Irritable Bowel Syndrome. Expert Opinion on Drug Metabolism and Toxicology. 2020 Jul; 16(7): 583-604. doi: 10.1080/17425255.2020.1767067. DOI: https://doi.org/10.1080/17425255.2020.1767067
Lacy BE, Gagnon-Sanschagrin P, Heimanson Z, Bungay R, Bellefleur R, Guérin A et al. Treatment-Free Interval: A Novel Approach to Assessing Real-World Treatment Effectiveness and Economic Impact Among Patients with Irritable Bowel Syndrome with Diarrhea. Advances in Therapy. 2024 Jun; 41(6): 2253-66. doi: 10.1007/s12325-024-02832-x. DOI: https://doi.org/10.1007/s12325-024-02832-x
García-Cedillo MF, Villegas-Garcia FU, Arenas-Martinez JS, Ornelas-Arroyo VJ, Yamamoto-Furusho JK, Estrella-Sato LA et al. Rifaximin-Alpha Increases Lactase Activity in Patients with Irritable Bowel Syndrome Without Constipation and Small Intestinal Bacterial Overgrowth. Digestive Diseases and Sciences. 2025 Jan; 70(1): 360-6. doi: 10.1007/s10620-024-08767-1. DOI: https://doi.org/10.1007/s10620-024-08767-1
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Pakistan Journal of Health Sciences
This work is licensed under a Creative Commons Attribution 4.0 International License.
This is an open-access journal and all the published articles / items are distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. For comments
